Accera, Inc. to Present at the 3rd Annual European Life Science CEO Forum for Partnering & Investing
February 1, 2010
Zurich, Switzerland, February 1, 2010 – Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today that it will present at the 3rd Annual European Life Science CEO Forum for Partnering & Investing February 11-12, 2010 at the ConventionPoint in Zurich, Switzerland.
Steve Orndorff, Ph.D., founder, president and CEO, will provide a corporate overview of Accera and an update on Axona® on Friday, February 12 at 11:15 a.m. CET in the Auditorium Room of the ConventionPoint.
Axona is a first-in-class prescription medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing ketone bodies as an alternative energy source for brain cells that have defective energy metabolism and can no longer utilize glucose. Axona has been shown to safely improve cognitive function and memory in AD patients and in pre-clinical animal models of dementia. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. Axona is a medical food as defined by the Orphan Drug Act and is regulated by the Food and Drug Administration. For more information about Axona, please visit www.about-axona.com or ask your physician.